Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global external neuromodulation market size was valued at USD 2.4 billion in 2024. The market is projected to grow from USD 2.7 billion in 2025 to USD 5.1 billion by 2031, exhibiting a CAGR of 10.3% during the forecast period. The U.S. market accounted for approximately 38% of global revenue in 2024, while China is expected to witness the highest growth rate among major economies.
External neuromodulation refers to non-invasive or minimally invasive therapies that modulate nervous system activity through electrical or magnetic stimulation. These technologies include Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), and Respiratory Electrical Stimulation (RES), among others. They offer therapeutic benefits for various neurological disorders without requiring surgical implantation.
The market growth is driven by increasing prevalence of neurological disorders, rising healthcare expenditure, and technological advancements in stimulation devices. Notably, the Transcutaneous Electrical Nerve Stimulation segment is projected to reach USD 1.8 billion by 2031. While North America currently dominates the market, Asia-Pacific is emerging as a high-growth region due to improving healthcare infrastructure and growing awareness about non-invasive treatment options.
Increasing Prevalence of Neurological Disorders
The global rise in neurological conditions such as chronic pain, migraine, epilepsy, and Parkinson's disease is a key driver for the external neuromodulation market. Over 1 billion people worldwide suffer from neurological disorders, creating significant demand for non-invasive treatment options.
Technological Advancements in Non-Invasive Devices
Recent innovations in wearable neuromodulation devices and transcranial magnetic stimulation (TMS) systems have significantly improved treatment efficacy. The development of smart, connected devices with AI capabilities is enhancing patient outcomes and driving adoption.
Regulatory approvals for new indications are expanding the addressable patient population for external neuromodulation therapies
The growing preference for drug-free pain management solutions and reduced side effects compared to pharmaceuticals is accelerating market growth.
MARKET CHALLENGES
High Cost of Treatment and Limited Reimbursement
The significant upfront costs of neuromodulation devices and limited insurance coverage in many regions create barriers to adoption. A full course of TMS therapy can cost between $6,000-$12,000, making it inaccessible for many patients.
Other Challenges
Lack of Awareness Among Patients and Providers
Many potential patients and even healthcare professionals remain unaware of external neuromodulation options, particularly in developing regions where these technologies are less established.
Stringent Regulatory Requirements
Medical device approval processes for external neuromodulation systems remain rigorous and time-consuming. The FDA classifies most neuromodulation devices as Class III, requiring extensive clinical data for approval, which delays market entry.
Expanding Applications in Mental Health
Emerging evidence supporting neuromodulation for depression, anxiety, and PTSD presents significant growth opportunities. The mental health application segment is projected to grow at over 12% annually as awareness increases.
Home-Use Devices and Telemedicine Integration
The development of FDA-cleared home-use neuromodulation devices and telehealth monitoring platforms is creating new revenue streams and improving patient accessibility to these therapies.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Transcutaneous Electrical Nerve Stimulation dominates as the most widely adopted technique due to its non-invasive nature and proven efficacy in pain management. Transcranial Magnetic Stimulation shows strong growth potential for neurological disorders, while Respiratory Electrical Stimulation remains a niche segment primarily used for respiratory rehabilitation. |
| By Application |
|
Spinal Cord Stimulation represents the most established application, particularly for chronic pain management. Deep Brain Stimulation is gaining traction for movement disorders, while Sacral Nerve Stimulation shows promise for bladder control applications. The others category includes emerging applications in gastrointestinal disorders and mental health conditions. |
| By End User |
|
Hospitals account for the majority share as they offer comprehensive neuromodulation services through dedicated pain management centers. Specialty clinics are growing rapidly for outpatient neuromodulation procedures, while research institutes drive innovation through clinical trials and pilot programs for new neuromodulation applications. |
| By Technology Maturity |
|
Established Technologies like TENS devices dominate current adoption, having gained widespread regulatory approvals. Growth phase technologies such as rTMS show increasing clinical acceptance, while emerging technologies in focused ultrasound neuromodulation represent the next frontier with substantial R&D investments from market leaders. |
| By Therapeutic Area |
|
Pain Management continues to be the primary therapeutic focus, supported by extensive clinical evidence. Neurological disorders represent a high-growth segment driven by aging populations, while psychiatric conditions show emerging potential as research validates neuromodulation's efficacy in depression and anxiety disorders. |
US and European Firms Dominate External Neuromodulation Market Share
The external neuromodulation market is led by established medical device manufacturers with strong R&D capabilities. Medtronic, Inc. (US) and Boston Scientific Corporation (US) collectively control approximately 40% of the global market revenue share. These companies benefit from comprehensive product portfolios covering transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and spinal cord stimulation systems.
Several specialized players have carved significant niches in specific neuromodulation segments. Nevro Corporation's HF10 therapy for chronic pain management and Neuronetics' NeuroStar TMS system for depression treatment represent technologically advanced solutions. Regional leaders like BioControl Medical (Israel) show strong presence in respiratory electrical stimulation devices.
List of Key External Neuromodulation Companies ProfiledSt. Jude Medical, Inc. (US)
Synapse Biomedical, Inc. (US)
Neurosigma, Inc. (US)
Neuropace, Inc. (US)
Cyberonics, Inc. (US)
BioControl Medical (Israel)
Abbott Laboratories (US)
CerboMed GmbH (Germany)
NeuroMetrix, Inc. (US)
Magstim Company Ltd. (UK)
The global External Neuromodulation market is projected to grow from millions in 2024 to $XX million by 2031, with a CAGR of X%. This growth is primarily fueled by increasing demand for non-invasive chronic pain treatment solutions. Transcutaneous Electrical Nerve Stimulation (TENS) devices account for approximately XX% of market revenue, followed by Transcranial Magnetic Stimulation at XX%.
Other TrendsTechnological Advancements in Device Portability
Recent innovations have led to smaller, wearable neuromodulation devices with longer battery life. Companies like Medtronic and Boston Scientific are investing heavily in Bluetooth-enabled devices that sync with mobile apps for real-time monitoring. The wearable segment is expected to grow at X% CAGR through 2031.
Geographic Expansion in Emerging MarketsWhile North America currently leads with XX% market share, Asia-Pacific is projected to be the fastest-growing region at X% CAGR, driven by expanding healthcare infrastructure in China and India. Europe maintains steady growth at X%, with Germany and France as key markets.
Regulatory Landscape ImpactFDA approvals for new indications (such as migraine and depression treatment) continue to expand market opportunities. The segment for psychiatric applications is growing at X% annually, though reimbursement policies remain a challenge in developing economies.
Competitive Landscape ConsolidationThe top 5 companies (Medtronic, Boston Scientific, Nevro Corporation, NeuroSigma, and BioControl Medical) hold approximately XX% of global market share. Recent mergers, acquisitions, and partnerships are reshaping competitive dynamics, with increased focus on home-use devices and digital health integration.
Regional Analysis: External Neuromodulation MarketEurope
Europe represents the second-largest market for external neuromodulation devices, benefiting from universal healthcare systems and strong neurological research programs. The region shows particularly rapid adoption in Germany, the UK, and Scandinavian countries. Strict CE marking requirements ensure high device standards while potentially slowing market entry for newer technologies. European neurologists demonstrate growing preference for non-pharmacological interventions due to concerns about opioid dependency. National health systems increasingly recognize the cost-effectiveness of neuromodulation for refractory conditions, leading to improved reimbursement. Cross-border collaborations facilitate knowledge sharing about optimal treatment protocols, though pricing pressures remain significant due to centralized procurement systems.
Asia-Pacific
Asia-Pacific emerges as the fastest-growing regional market, with Japan, South Korea, and Australia leading adoption trends. Expanding neurological treatment centers and improving healthcare access drive market growth across developed nations. Cultural acceptance of non-invasive therapies complements traditional medicine approaches in many Asian countries. Governments invest in neurological care infrastructure while medical tourism creates demand for advanced neuromodulation treatments. Challenges include price sensitivity in developing markets and varied regulatory timelines. Local manufacturers gain traction with cost-competitive devices, though premium international brands dominate the high-end segment. Regional collaborations aim to standardize training and treatment protocols across diverse healthcare systems.
South America
South America's external neuromodulation market grows steadily, concentrated in Brazil, Argentina, and Chile. Urban specialty centers adopt advanced systems while rural areas show limited penetration. Economic volatility affects device affordability and hospital procurement budgets. Neurologists demonstrate strong interest in training programs to expand treatment capacity. Governments prioritize neurological care but face challenges implementing comprehensive coverage policies. The region participates in multinational clinical trials, improving access to experimental therapies. Local production remains limited, making the region dependent on imports with associated cost and regulatory hurdles.
Middle East & Africa
The MEA region presents uneven development, with Gulf Cooperation Council countries leading adoption through specialized neurological centers. High-end medical tourism destinations incorporate advanced neuromodulation into comprehensive treatment packages. Budget constraints in Africa limit access to conventional pharmaceuticals, let alone neuromodulation technologies. Philanthropic initiatives introduce basic devices in select urban centers. Regulatory frameworks vary significantly between nations, creating market fragmentation. Promising growth exists in affluent regions prioritizing neurological care modernization, while conflict zones and underdeveloped areas remain largely untapped.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Medical device manufacturers
Healthcare providers and hospitals
Neurology research institutions
Investors and venture capitalists
Policy makers and regulatory bodies
-> Global external neuromodulation market was valued at USD 2.4 billion in 2024 and is expected to reach USD 5.1 billion by 2031, growing at a CAGR of 10.3%.
Which key companies operate in Global External Neuromodulation Market?
-> Key players include Medtronic, Boston Scientific, St. Jude Medical, Nevro Corporation, and Neuronetics, among others.
-> Key growth drivers include rising neurological disorder prevalence, healthcare spending, and technological advancements.
-> North America accounted for 38% of global revenue in 2024, while Asia-Pacific shows the highest growth potential.
-> Emerging trends include non-invasive stimulation technologies and expanding applications in neurological therapies.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates